An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban
Mei H, Wang J, Ma S. An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban. Journal Of Clinical Epidemiology 2021, 139: 28-37. PMID: 34271110, DOI: 10.1016/j.jclinepi.2021.07.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntithrombinsAtrial FibrillationDabigatranFemaleHumansMaleMedicareRivaroxabanStrokeTreatment OutcomeUnited StatesConceptsNon-valvular atrial fibrillation patientsSafety of rivaroxabanAtrial fibrillation patientsMultiple chronic conditionsInclusion/exclusion criteriaTrial analysisMajor bleedingOral anticoagulantsThromboembolic eventsFibrillation patientsTreatment regimensChronic conditionsClinical trialsMedicare patientsDabigatranExclusion criteriaMedicare dataRivaroxabanStudy designRelative efficacyIndividual trialsTrialsPatientsStrokePrimary event